B型肝炎ウイルス(Hepatitis B):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Hepatitis B - Pipeline Review, H2 2014
◆商品コード:GMDHC5679IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:317
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるB型肝炎ウイルス(Hepatitis B)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・B型肝炎ウイルス(Hepatitis B)の概要
・B型肝炎ウイルス(Hepatitis B)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・B型肝炎ウイルス(Hepatitis B)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・B型肝炎ウイルス(Hepatitis B)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・B型肝炎ウイルス(Hepatitis B)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Hepatitis B – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Hepatitis B – Pipeline Review, H2 2014’, provides an overview of the Hepatitis B’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatitis B, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis B and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hepatitis B
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hepatitis B and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hepatitis B products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatitis B pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hepatitis B
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hepatitis B pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 8
List of Figures 10
Introduction 11
Global Markets Direct Report Coverage 11
Hepatitis B Overview 12
Therapeutics Development 13
Pipeline Products for Hepatitis B – Overview 13
Pipeline Products for Hepatitis B – Comparative Analysis 14
Hepatitis B – Therapeutics under Development by Companies 15
Hepatitis B – Therapeutics under Investigation by Universities/Institutes 23
Hepatitis B – Pipeline Products Glance 24
Late Stage Products 24
Clinical Stage Products 25
Early Stage Products 26
Unknown Stage Products 27
Hepatitis B – Products under Development by Companies 28
Hepatitis B – Products under Investigation by Universities/Institutes 36
Hepatitis B – Companies Involved in Therapeutics Development 37
Abivax 37
AiCuris GmbH & Co. KG 38
Akshaya Bio Inc. 39
Alnylam Pharmaceuticals, Inc. 40
AlphaMab Co., Ltd 41
AltraVax Inc. 42
Amarna Therapeutics B.V. 43
Arrowhead Research Corporation 44
Assembly Biosciences, Inc. 45
Beijing Minhai Biotechnology Co., Ltd 46
Benitec Biopharma Limited 47
Big DNA Ltd. 48
BioDiem Ltd 49
Biological E. Limited 50
BioStar Pharmaceuticals, Inc. 51
Bolder Biotechnology, Inc. 52
Bukwang Pharm.Co., Ltd. 53
CEL-SCI Corporation 54
Celltrion, Inc. 55
Chiasma, Inc. 56
Chimerix, Inc. 57
Chongqing Zhifei Biological Products Co., Ltd. 58
ChronTech Pharma AB 59
Colby Pharmaceutical Company 60
Dynavax Technologies Corporation 61
F. Hoffmann-La Roche Ltd. 62
GeneCure LLC 63
Genexine, Inc. 64
Gilead Sciences, Inc. 65
GlaxoSmithKline plc 66
GlobalAcorn 67
Green Cross Corporation 68
HEC Pharm Co., Ltd. 69
Humabs BioMed SA 70
Ildong Pharmaceutical Co., Ltd. 71
Immune Targeting Systems (ITS) Ltd. 72
Immunovaccine, Inc. 73
Inbiopro Solutions Pvt. Ltd. 74
Indian Immunologicals Limited 75
Isis Pharmaceuticals, Inc. 76
Johnson & Johnson 77
Leukocare AG 78
LG Life Sciences, Ltd. 79
Ligand Pharmaceuticals, Inc. 80
Mologen AG 81
Mucosis B.V. 82
NeuroVive Pharmaceutical AB 83
Novira Therapeutics, Inc. 84
Panacea Biotec Limited 85
PharmaEssentia Corporation 86
REPLICor Inc. 87
RFS Pharma, LLC 88
Romark Laboratories, L.C. 89
Sanofi Pasteur SA 90
Scynexis, Inc. 91
Seek 92
Sinovac Biotech Ltd. 93
SK Chemicals Co., Ltd. 94
SomaGenics Inc. 95
Spring Bank Pharmaceuticals, Inc. 96
TCM Biotech International Corp 97
Tekmira Pharmaceuticals Corp. 98
TetraLogic Pharmaceuticals 99
Therametrics holding AG 100
THERAVECTYS SA 101
Transgene SA 102
Uni-Bio Science Group Ltd. 103
Vaxart, Inc. 104
Vaxine Pty Ltd 105
VLP Biotech, Inc. 106
WaterStone Pharmaceuticals, Inc. 107
Hepatitis B – Therapeutics Assessment 108
Assessment by Monotherapy Products 108
Assessment by Combination Products 109
Assessment by Target 110
Assessment by Mechanism of Action 113
Assessment by Route of Administration 115
Assessment by Molecule Type 117
Drug Profiles 119
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine – Drug Profile 119
ABX-196 – Drug Profile 121
ABX-203 – Drug Profile 122
acALY-18 – Drug Profile 123
AGX-1009 – Drug Profile 124
AIC-649 – Drug Profile 125
ALN-HBV – Drug Profile 126
amdoxovir – Drug Profile 127
ARC-520 – Drug Profile 128
BBT-012 – Drug Profile 130
BDNA-001 – Drug Profile 131
besifovir – Drug Profile 132
birinapant – Drug Profile 134
CEL-1000 – Drug Profile 137
ChronVac-B – Drug Profile 139
clevudine – Drug Profile 140
CMX-157 – Drug Profile 142
CpAM Gen-1 – Drug Profile 143
CpAM Gen-2 – Drug Profile 144
CPI-43132 – Drug Profile 145
Creaferon – Drug Profile 146
CTP-24 – Drug Profile 147
cTP-5 – Drug Profile 148
DasKloster-0039-01 – Drug Profile 149
Dendritic Cell Therapy for Hepatitis B – Drug Profile 150
diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine – Drug Profile 151
diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [type B] + polio (hexavalent) vaccine – Drug Profile 152
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine – Drug Profile 153
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine – Drug Profile 154
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine – Drug Profile 155
Drug for Hepatitis B – Drug Profile 156
Drugs for Hepatitis B Virus Infections – Drug Profile 157
DVR-23 – Drug Profile 158
FP-02 – Drug Profile 159
GA-5NM-HBV – Drug Profile 160
GC-1102 – Drug Profile 161
Gene Therapy for Hepatitis B and Hepatitis C – Drug Profile 162
GLS-4 – Drug Profile 163
GS-4774 – Drug Profile 164
GS-9620 – Drug Profile 165
GSK-217744 – Drug Profile 167
GSK-2231392A – Drug Profile 168
HB-110E – Drug Profile 169
Hepabulin – Drug Profile 171
hepatitis A + hepatitis B vaccine – Drug Profile 172
Hepatitis B Surface Antigen Secretion Inhibitor – Drug Profile 173
Hepatitis B Vaccine – Drug Profile 174
hepatitis B vaccine – Drug Profile 176
hepatitis B vaccine – Drug Profile 177
hepatitis B vaccine – Drug Profile 178
hepatitis B vaccine – Drug Profile 179
hepatitis B vaccine – Drug Profile 180
hepatitis B vaccine – Drug Profile 181
hepatitis B vaccine – Drug Profile 182
hepatitis B vaccine – Drug Profile 183
hepatitis B vaccine – Drug Profile 184
hepatitis B vaccine – Drug Profile 185
hepatitis B vaccine – Drug Profile 186
hepatitis B vaccine – Drug Profile 187
hepatitis B vaccine – Drug Profile 188
hepatitis B vaccine – Drug Profile 189
hepatitis B vaccine – Drug Profile 190
hepatitis B vaccine – Drug Profile 191
hepatitis B vaccine – Drug Profile 192
hepatitis B vaccine (HBcAg and HBsAg) – Drug Profile 193
hepatitis B vaccine (HBcAg) – Drug Profile 194
hepatitis-B vaccine – Drug Profile 195
HepB Vaccine – Drug Profile 196
HepB-nRNA – Drug Profile 197
Hepbarna – Drug Profile 198
IBPB-006IA – Drug Profile 200
INO-1800 – Drug Profile 201
interferon alfa-2a – Drug Profile 203
interferon alfa-2b – Drug Profile 204
ISIS-HBVRx – Drug Profile 205
JVRS-100 + HBV Vaccine – Drug Profile 206
KN-003 – Drug Profile 207
KW-1 – Drug Profile 208
KW-2 – Drug Profile 209
MGN-1333 – Drug Profile 210
Monoclonal Antibody for HBV Infections – Drug Profile 211
Monoclonal Antibody for Hepatitis B – Drug Profile 212
Myrcludex-B – Drug Profile 213
Novaferon – Drug Profile 215
NVP-018 – Drug Profile 217
NVR-3778 – Drug Profile 218
PEG-IFN-SA – Drug Profile 219
peginterferon alfa-2b – Drug Profile 220
pradefovir mesylate – Drug Profile 222
Prophylactic Hepatitis B Vaccine – Drug Profile 223
Protein for Hepatitis C, Hepatitis B and Cancer – Drug Profile 224
REP-9-AC – Drug Profile 225
REP-9-AC’ – Drug Profile 227
RG-7795 – Drug Profile 229
RM-5038 – Drug Profile 231
RNAi Oligonucleotide for Hepatitis B – Drug Profile 232
SB-9200 – Drug Profile 233
SCY-635 – Drug Profile 235
Small Molecule for Hepatitis B – Drug Profile 237
Small Molecule for Liver Cancer and Hepatitis B – Drug Profile 238
Small Molecule to Inhibit Capsid Protein for Hepatitis B – Drug Profile 239
Small Molecule to Inhibit cccDNA for Hepatitis B – Drug Profile 240
Small Molecules for Bacterial and Viral Infections – Drug Profile 241
Small Molecules for Hepatitis B – Drug Profile 243
Small Molecules for Hepatitis B – Drug Profile 244
Small Molecules for Hepatitis B Infections – Drug Profile 245
Small Molecules for Viral Infections – Drug Profile 246
Small Molecules to Inhibit HBx for Hepatitis B and Hepatocellular Carcinoma – Drug Profile 247
Small Molecules to Inhibit Reverse Transcriptase for Hepatitis B – Drug Profile 248
Small Molecules to Target Caspase and Inhibitor Of Apoptosis Protein for Cancer and Hepatitis B Virus Infection – Drug Profile 249
TCM-800B – Drug Profile 250
tenofovir alafenamide – Drug Profile 251
TG-1050 – Drug Profile 252
Therapeutic Hepatitis B Vaccine – Drug Profile 253
TKM-HBV – Drug Profile 254
Vaccine for Cancer and Hepatitis B – Drug Profile 255
Vaccine for Hepatitis – Drug Profile 256
W-28F – Drug Profile 257
Y-101 – Drug Profile 258
Hepatitis B – Recent Pipeline Updates 259
Hepatitis B – Dormant Projects 292
Hepatitis B – Discontinued Products 299
Hepatitis B – Product Development Milestones 300
Featured News & Press Releases 300
Appendix 308
Methodology 308
Coverage 308
Secondary Research 308
Primary Research 308
Expert Panel Validation 308
Contact Us 309
Disclaimer 309

[List of Tables]
Number of Products under Development for Hepatitis B, H2 2014 21
Number of Products under Development for Hepatitis B - Comparative Analysis, H2 2014 22
Number of Products under Development by Companies, H2 2014 24
Number of Products under Development by Companies, H2 2014 (Contd..1) 25
Number of Products under Development by Companies, H2 2014 (Contd..2) 26
Number of Products under Development by Companies, H2 2014 (Contd..3) 27
Number of Products under Development by Companies, H2 2014 (Contd..4) 28
Number of Products under Development by Companies, H2 2014 (Contd..5) 29
Number of Products under Development by Companies, H2 2014 (Contd..6) 30
Number of Products under Investigation by Universities/Institutes, H2 2014 31
Comparative Analysis by Late Stage Development, H2 2014 32
Comparative Analysis by Clinical Stage Development, H2 2014 33
Comparative Analysis by Early Stage Development, H2 2014 34
Comparative Analysis by Unknown Stage Development, H2 2014 35
Products under Development by Companies, H2 2014 36
Products under Development by Companies, H2 2014 (Contd..1) 37
Products under Development by Companies, H2 2014 (Contd..2) 38
Products under Development by Companies, H2 2014 (Contd..3) 39
Products under Development by Companies, H2 2014 (Contd..4) 40
Products under Development by Companies, H2 2014 (Contd..5) 41
Products under Development by Companies, H2 2014 (Contd..6) 42
Products under Development by Companies, H2 2014 (Contd..7) 43
Products under Investigation by Universities/Institutes, H2 2014 44
Hepatitis B - Pipeline by Abivax, H2 2014 45
Hepatitis B - Pipeline by AiCuris GmbH & Co. KG, H2 2014 46
Hepatitis B - Pipeline by Akshaya Bio Inc., H2 2014 47
Hepatitis B - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2014 48
Hepatitis B - Pipeline by AlphaMab Co., Ltd, H2 2014 49
Hepatitis B - Pipeline by AltraVax Inc., H2 2014 50
Hepatitis B - Pipeline by Amarna Therapeutics B.V., H2 2014 51
Hepatitis B - Pipeline by Arrowhead Research Corporation, H2 2014 52
Hepatitis B - Pipeline by Assembly Biosciences, Inc., H2 2014 53
Hepatitis B - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2014 54
Hepatitis B - Pipeline by Benitec Biopharma Limited, H2 2014 55
Hepatitis B - Pipeline by Big DNA Ltd., H2 2014 56
Hepatitis B - Pipeline by BioDiem Ltd, H2 2014 57
Hepatitis B - Pipeline by Biological E. Limited, H2 2014 58
Hepatitis B - Pipeline by BioStar Pharmaceuticals, Inc., H2 2014 59
Hepatitis B - Pipeline by Bolder Biotechnology, Inc., H2 2014 60
Hepatitis B - Pipeline by Bukwang Pharm.Co., Ltd., H2 2014 61
Hepatitis B - Pipeline by CEL-SCI Corporation, H2 2014 62
Hepatitis B - Pipeline by Celltrion, Inc., H2 2014 63
Hepatitis B - Pipeline by Chiasma, Inc., H2 2014 64
Hepatitis B - Pipeline by Chimerix, Inc., H2 2014 65
Hepatitis B - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2014 66
Hepatitis B - Pipeline by ChronTech Pharma AB, H2 2014 67
Hepatitis B - Pipeline by Colby Pharmaceutical Company, H2 2014 68
Hepatitis B - Pipeline by Dynavax Technologies Corporation, H2 2014 69
Hepatitis B - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 70
Hepatitis B - Pipeline by GeneCure LLC, H2 2014 71
Hepatitis B - Pipeline by Genexine, Inc., H2 2014 72
Hepatitis B - Pipeline by Gilead Sciences, Inc., H2 2014 73
Hepatitis B - Pipeline by GlaxoSmithKline plc, H2 2014 74
Hepatitis B - Pipeline by GlobalAcorn, H2 2014 75
Hepatitis B - Pipeline by Green Cross Corporation, H2 2014 76
Hepatitis B - Pipeline by HEC Pharm Co., Ltd., H2 2014 77
Hepatitis B - Pipeline by Humabs BioMed SA, H2 2014 78
Hepatitis B - Pipeline by Ildong Pharmaceutical Co., Ltd., H2 2014 79
Hepatitis B - Pipeline by Immune Targeting Systems (ITS) Ltd., H2 2014 80
Hepatitis B - Pipeline by Immunovaccine, Inc., H2 2014 81
Hepatitis B - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2014 82
Hepatitis B - Pipeline by Indian Immunologicals Limited, H2 2014 83
Hepatitis B - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 84
Hepatitis B - Pipeline by Johnson & Johnson, H2 2014 85
Hepatitis B - Pipeline by Leukocare AG, H2 2014 86
Hepatitis B - Pipeline by LG Life Sciences, Ltd., H2 2014 87
Hepatitis B - Pipeline by Ligand Pharmaceuticals, Inc., H2 2014 88
Hepatitis B - Pipeline by Mologen AG, H2 2014 89
Hepatitis B - Pipeline by Mucosis B.V., H2 2014 90
Hepatitis B - Pipeline by NeuroVive Pharmaceutical AB, H2 2014 91
Hepatitis B - Pipeline by Novira Therapeutics, Inc., H2 2014 92
Hepatitis B - Pipeline by Panacea Biotec Limited, H2 2014 93
Hepatitis B - Pipeline by PharmaEssentia Corporation, H2 2014 94
Hepatitis B - Pipeline by REPLICor Inc., H2 2014 95
Hepatitis B - Pipeline by RFS Pharma, LLC, H2 2014 96
Hepatitis B - Pipeline by Romark Laboratories, L.C., H2 2014 97
Hepatitis B - Pipeline by Sanofi Pasteur SA, H2 2014 98
Hepatitis B - Pipeline by Scynexis, Inc., H2 2014 99
Hepatitis B - Pipeline by Seek, H2 2014 100
Hepatitis B - Pipeline by Sinovac Biotech Ltd., H2 2014 101
Hepatitis B - Pipeline by SK Chemicals Co., Ltd., H2 2014 102
Hepatitis B - Pipeline by SomaGenics Inc., H2 2014 103
Hepatitis B - Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2014 104
Hepatitis B - Pipeline by TCM Biotech International Corp, H2 2014 105
Hepatitis B - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014 106
Hepatitis B - Pipeline by TetraLogic Pharmaceuticals, H2 2014 107
Hepatitis B - Pipeline by Therametrics holding AG, H2 2014 108
Hepatitis B - Pipeline by THERAVECTYS SA, H2 2014 109
Hepatitis B - Pipeline by Transgene SA, H2 2014 110
Hepatitis B - Pipeline by Uni-Bio Science Group Ltd., H2 2014 111
Hepatitis B - Pipeline by Vaxart, Inc., H2 2014 112
Hepatitis B - Pipeline by Vaxine Pty Ltd, H2 2014 113
Hepatitis B - Pipeline by VLP Biotech, Inc., H2 2014 114
Hepatitis B - Pipeline by WaterStone Pharmaceuticals, Inc., H2 2014 115
Assessment by Monotherapy Products, H2 2014 116
Assessment by Combination Products, H2 2014 117
Number of Products by Stage and Target, H2 2014 119
Number of Products by Stage and Mechanism of Action, H2 2014 122
Number of Products by Stage and Route of Administration, H2 2014 124
Number of Products by Stage and Molecule Type, H2 2014 126
Hepatitis B Therapeutics - Recent Pipeline Updates, H2 2014 267
Hepatitis B - Dormant Projects, H2 2014 300
Hepatitis B - Dormant Projects (Contd..1), H2 2014 301
Hepatitis B - Dormant Projects (Contd..2), H2 2014 302
Hepatitis B - Dormant Projects (Contd..3), H2 2014 303
Hepatitis B - Dormant Projects (Contd..4), H2 2014 304
Hepatitis B - Dormant Projects (Contd..5), H2 2014 305
Hepatitis B - Dormant Projects (Contd..6), H2 2014 306
Hepatitis B - Discontinued Products, H2 2014 307

[List of Figures]
Number of Products under Development for Hepatitis B, H2 2014 21
Number of Products under Development for Hepatitis B - Comparative Analysis, H2 2014 22
Number of Products under Development by Companies, H2 2014 23
Number of Products under Investigation by Universities/Institutes, H2 2014 31
Comparative Analysis by Late Stage Development, H2 2014 32
Comparative Analysis by Clinical Stage Development, H2 2014 33
Comparative Analysis by Early Stage Products, H2 2014 34
Assessment by Monotherapy Products, H2 2014 116
Assessment by Combination Products, H2 2014 117
Number of Products by Top 10 Targets, H2 2014 118
Number of Products by Stage and Top 10 Targets, H2 2014 118
Number of Products by Top 10 Mechanism of Actions, H2 2014 121
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 121
Number of Products by Top 10 Routes of Administration, H2 2014 123
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 124
Number of Products by Top 10 Molecule Types, H2 2014 125
Number of Products by Stage and Top 10 Molecule Types, H2 2014 125

【掲載企業】

Abivax
AiCuris GmbH & Co. KG
Akshaya Bio Inc.
Alnylam Pharmaceuticals, Inc.
AlphaMab Co., Ltd
AltraVax Inc.
Amarna Therapeutics B.V.
Arrowhead Research Corporation
Assembly Biosciences, Inc.
Beijing Minhai Biotechnology Co., Ltd
Benitec Biopharma Limited
Big DNA Ltd.
BioDiem Ltd
Biological E. Limited
BioStar Pharmaceuticals, Inc.
Bolder Biotechnology, Inc.
Bukwang Pharm.Co., Ltd.
CEL-SCI Corporation
Celltrion, Inc.
Chiasma, Inc.
Chimerix, Inc.
Chongqing Zhifei Biological Products Co., Ltd.
ChronTech Pharma AB
Colby Pharmaceutical Company
Dynavax Technologies Corporation
F. Hoffmann-La Roche Ltd.
GeneCure LLC
Genexine, Inc.
Gilead Sciences, Inc.
GlaxoSmithKline plc
GlobalAcorn
Green Cross Corporation
HEC Pharm Co., Ltd.
Humabs BioMed SA
Ildong Pharmaceutical Co., Ltd.
Immune Targeting Systems (ITS) Ltd.
Immunovaccine, Inc.
Inbiopro Solutions Pvt. Ltd.
Indian Immunologicals Limited
Isis Pharmaceuticals, Inc.
Johnson & Johnson
Leukocare AG
LG Life Sciences, Ltd.
Ligand Pharmaceuticals, Inc.
Mologen AG
Mucosis B.V.
NeuroVive Pharmaceutical AB
Novira Therapeutics, Inc.
Panacea Biotec Limited
PharmaEssentia Corporation
REPLICor Inc.
RFS Pharma, LLC
Romark Laboratories, L.C.
Sanofi Pasteur SA
Scynexis, Inc.
Seek
Sinovac Biotech Ltd.
SK Chemicals Co., Ltd.
SomaGenics Inc.
Spring Bank Pharmaceuticals, Inc.
TCM Biotech International Corp
Tekmira Pharmaceuticals Corp.
TetraLogic Pharmaceuticals
Therametrics holding AG
THERAVECTYS SA
Transgene SA
Uni-Bio Science Group Ltd.
Vaxart, Inc.
Vaxine Pty Ltd
VLP Biotech, Inc.
WaterStone Pharmaceuticals, Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[B型肝炎ウイルス(Hepatitis B):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆